These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28748718)

  • 1. Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.
    Tuccori M; Convertino I; Galiulo MT; Marino A; Capogrosso-Sansone A; Blandizzi C
    Expert Opin Drug Saf; 2017 Oct; 16(10):1133-1148. PubMed ID: 28748718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetes and cancer risk: oncologic considerations].
    Rosta A
    Orv Hetil; 2011 Jul; 152(29):1144-55. PubMed ID: 21712179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihyperglycaemic therapies and cancer risk.
    Lutz SZ; Staiger H; Fritsche A; Häring HU
    Diab Vasc Dis Res; 2014 Nov; 11(6):371-89. PubMed ID: 25231191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.
    Filippatos T; Tzavella E; Rizos C; Elisaf M; Liamis G
    Expert Opin Drug Saf; 2017 Oct; 16(10):1121-1132. PubMed ID: 28748724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the cardiovascular risk with non-insulin antidiabetic drugs.
    Athyros VG; Imprialos K; Stavropoulos K; Sahinidis A; Doumas M
    Expert Opin Drug Saf; 2019 Mar; 18(3):241-251. PubMed ID: 30810055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.
    Singh S
    Curr Diab Rep; 2014 Dec; 14(12):563. PubMed ID: 25363547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapy of type 2 diabetes. Critical evaluation of oral antidiabetic drugs].
    Landgraf R
    MMW Fortschr Med; 2000 May; 142(21):33-7. PubMed ID: 10872292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
    Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
    Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.
    Panicker GK; Karnad DR; Salvi V; Kothari S
    J Assoc Physicians India; 2012 Jan; 60():56-61. PubMed ID: 22715547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs.
    McFarland MS; Cripps R
    Pharmacotherapy; 2010 Nov; 30(11):1159-78. PubMed ID: 20973689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin and other antidiabetic drugs and hepatocellular carcinoma risk: a nested case-control study based on Italian healthcare utilization databases.
    Bosetti C; Franchi M; Nicotra F; Asciutto R; Merlino L; La Vecchia C; Corrao G
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):771-8. PubMed ID: 26013675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Oral antidiabetics and lipids].
    Verges B
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S45-50. PubMed ID: 12037508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin and the risk of head and neck cancer: a case-control analysis.
    Becker C; Jick SS; Meier CR; Bodmer M
    Diabetes Obes Metab; 2014 Nov; 16(11):1148-54. PubMed ID: 25041125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire?
    Gallagher EJ; LeRoith D
    Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):485-94. PubMed ID: 23974779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2014 Jun; 10(6):839-57. PubMed ID: 24669954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing?
    Klil-Drori AJ; Azoulay L; Pollak MN
    Nat Rev Clin Oncol; 2017 Feb; 14(2):85-99. PubMed ID: 27502359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.